LDT(Laboratory Developed Tests) 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Laboratory Developed Test Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 7,088,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,352,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,055,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

주요 조사 결과

• LDT(Laboratory Developed Tests) 시장 규모 : 90억 달러(2025년)
• 예상 시장 규모 : 139억 달러(2032년)
• 세계 시장 성장률 : 6.4%(2025-2032년 CAGR)

LDT(Laboratory Developed Tests) 시장 - 보고서 범위

LDT(Laboratory Developed Tests) 시장에는 단일 실험실 내에서 설계, 제조 및 사용되는 진단 검사가 포함됩니다. LDT는 종양, 유전, 감염, 희귀질환, 희귀질환 등 특수한 진단 분야에서 널리 사용되고 있으며, 환자 집단이나 새로운 건강 위협에 맞춤화된 솔루션을 제공하기 때문에 상업적으로 이용 가능한 대체품이 없는 경우 특히 중요합니다. 맞춤형 의료에 대한 수요 증가, 만성질환 및 감염성 질환의 유행, 분자진단의 기술적 진보가 시장 성장의 주요 요인으로 작용하고 있습니다.

시장 성장 촉진요인

여러 요인이 세계 LDT(Laboratory Developed Tests) 시장의 성장을 촉진하고 있습니다. 맞춤형 의료의 급속한 발전과 맞춤형 진단 솔루션에 대한 요구가 LDT의 사용을 촉진하고 있습니다. 특히 분자진단과 차세대 시퀀싱의 기술 발전은 이러한 검사의 속도, 정확성, 신뢰성을 크게 향상시키고 있습니다. 또한, 전 세계적으로 암, 유전성 질환 및 감염성 질환의 부담이 증가함에 따라 전문적이고 유연한 진단 옵션에 대한 수요가 증가하고 있으며, COVID-19 팬데믹은 신속하고 적응력 있는 진단 도구의 중요성을 더욱 부각시키며 LDT에 대한 인식과 규제 당국의 지지를 촉진했습니다. 진단 연구에 대한 투자 증가와 새로운 분석법 개발에 대한 학술 연구 기관의 역할 증가도 시장 발전을 촉진하고 있습니다.

시장 억제요인

이러한 장점에도 불구하고 LDT(Laboratory Developed Tests) 시장은 여러 가지 도전에 직면해 있습니다. 가장 큰 우려는 지역 간 규제 감독이 통일되어 있지 않아 검사 품질과 환자 안전에 편차가 발생할 수 있다는 점입니다. 향후 예정된 규제 변경, 특히 미국에서 제안된 VALID Act에 근거한 규제 변경은 검사 시설에 더 엄격한 규정 준수 부담을 부과하고, 경영 비용을 증가시키며, 기술 혁신을 제한할 수 있습니다. 또한, LDT는 많은 경우 상당한 전문 지식과 인프라를 필요로 하기 때문에 특히 자원이 부족한 환경에서는 보급이 제한될 수 있습니다. 재현성, 검증 및 표준화에 대한 우려는 광범위한 채택을 더욱 방해합니다. 마지막으로, FDA가 승인한 상업용 검사와의 경쟁으로 인해 특정 응용 분야에서 LDT의 시장 점유율이 감소할 수 있습니다.

시장 기회

LDT 시장은 진단 분야의 지속적인 기술 혁신과 정밀의료의 확대로 인해 큰 성장 기회를 제공하고 있습니다. 임상 검사에 AI와 바이오인포매틱스의 통합이 진행됨에 따라 보다 정확하고 효율적인 검사 개발을 위한 새로운 가능성이 열리고 있습니다. 특히 아시아태평양과 라틴아메리카 등 신흥 경제권에서는 의료 인프라와 진단 능력이 향상되고 있어 LDT 도입의 새로운 길이 열리고 있습니다. 또한, 질병의 조기 발견과 표적치료에 대한 수요가 증가함에 따라 LDT는 희귀질환, 약리유전체학 등 틈새 진단 분야에서 중심적인 역할을 할 수 있는 유리한 위치에 있습니다. 또한, 학술 연구 센터와 상업적 진단 기업 간의 제휴는 LDT 개발 및 시장에서의 활동 범위를 가속화할 수 있습니다.

이 보고서는 세계 LDT(Laboratory Developed Tests) 시장에 대해 조사했으며, 성장 촉진요인, 동향, 기회, 과제 등 시장 역학에 대한 상세한 분석을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 주요 동향
• 거시경제 요인
  • 세계의 부문 전망
  • 세계의 GDP 성장 전망
• COVID-19의 영향 분석
• 예측요인 - 관련성과 영향

제3장 부가가치 인사이트

• 제품 채용 분석
• 규제 상황
• 상환 시나리오
• PESTLE 분석
• 프로모션 전략 : 주요 기업별

제4장 세계의 LDT(Laboratory Developed Tests) 전망

• 주요 하이라이트
  • 시장 규모와 전년비 성장
  • 절대적 수익 기회
• 시장 규모 분석과 예측
  • 시장 규모 실적 분석(2019-2024년)
  • 현재 시장 규모 분석과 예측(2025-2032년)
• 세계의 LDT(Laboratory Developed Tests) 전망 : 검사 유형
  • 소개/주요 조사 결과
  • 시장 규모 실적 분석 : 검사 유형별(2019-2024년)
  • 현재 시장 규모 분석과 예측 : 검사 유형별(2025-2032년)
  • 시장 매력 분석 : 검사 유형
• 세계의 LDT(Laboratory Developed Tests) 전망 : 용도
  • 소개/주요 조사 결과
  • 시장 규모 실적 : 용도별(2019-2024년)
  • 현재 시장 규모 분석과 예측 : 용도별(2025-2032년)
  • 시장 매력 분석 : 용도
• 세계의 LDT(Laboratory Developed Tests) 전망 : 최종사용자
  • 소개/주요 조사 결과
  • 시장 규모 실적 : 최종사용자별(2019-2024년)
  • 현재 시장 규모 분석과 예측 : 최종사용자별(2025-2032년)
  • 시장 매력 분석 : 최종사용자

제5장 세계의 LDT(Laboratory Developed Tests) 전망 : 지역

• 주요 하이라이트
• 시장 규모 실적 분석 : 지역별(2019-2024년)
• 현재 시장 규모 분석과 예측 : 지역별(2025-2032년)
  • 북미
  • 유럽
  • 동아시아
  • 남아시아 및 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력 분석 : 지역

제6장 북미의 LDT(Laboratory Developed Tests) 전망

제7장 유럽의 LDT(Laboratory Developed Tests) 전망

제8장 동아시아의 LDT(Laboratory Developed Tests) 전망

제9장 남아시아 및 오세아니아의 LDT(Laboratory Developed Tests) 전망

제10장 라틴아메리카의 LDT(Laboratory Developed Tests) 전망

제11장 중동 및 아프리카의 LDT(Laboratory Developed Tests) 전망

제12장 경쟁 구도

• 시장 점유율 분석(2025년)
• 시장 구조
  • 경쟁 강도 맵 : 시장별
  • 경쟁 대시보드
• 기업 개요(상세 - 개요, 재무, 전략, 최근 발전)
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Kaneka Eurogentec SA
  • Vastian
  • Roche Diagnostics
  • Adaptive Biotechnologies.
  • Guardant Health, Inc.
  • Smiths Medical
  • Quest Diagnostics
  • Beckman Coulter
  • OPKO Health, Inc.
  • Siemens Medical Solutions USA, Inc.
  • Quanterix
  • Proteomics International

제13장 부록

ksm

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Laboratory Developed Test (LDT) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Laboratory Developed Test Market Size (2025E): US$ 9.0 Bn
• Projected Market Value (2032F): US$ 13.9 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 6.4%

Laboratory Developed Test Market - Report Scope:

The Laboratory Developed Test (LDT) market encompasses diagnostic tests that are designed, manufactured, and used within a single laboratory. These tests are particularly vital when no commercially available alternatives exist, providing solutions tailored for unique patient populations or emerging health threats. LDTs are widely used in specialized diagnostic areas such as oncology, genetics, infectious diseases, and rare disorders. The increasing demand for personalized medicine, rising prevalence of chronic and infectious diseases, and technological advancements in molecular diagnostics are key contributors to market growth.

Market Growth Drivers:

Several key factors are fueling the growth of the global Laboratory Developed Test market. The rapid rise in personalized medicine and the need for customized diagnostic solutions are encouraging the use of LDTs. Technological advancements, especially in molecular diagnostics and next-generation sequencing, have significantly improved the speed, accuracy, and reliability of these tests. Moreover, the growing burden of cancer, genetic disorders, and infectious diseases globally has amplified the demand for specialized and flexible diagnostic options. The COVID-19 pandemic further highlighted the importance of rapid and adaptable diagnostic tools, driving both awareness and regulatory support for LDTs. Increasing investments in diagnostic research and the growing role of academic and research institutions in developing novel assays also propel the market forward.

Market Restraints:

Despite their advantages, the Laboratory Developed Test market faces several challenges. A key concern is the lack of uniform regulatory oversight across regions, which can lead to variability in test quality and patient safety. The upcoming regulatory changes, particularly in the United States under the proposed VALID Act, could impose stricter compliance burdens on labs, increasing operational costs and limiting innovation. In addition, LDTs often require significant expertise and infrastructure, restricting their widespread use, especially in low-resource settings. Concerns around reproducibility, validation, and standardization further hinder broader adoption. Lastly, competition from FDA-approved commercial tests can reduce the market share for LDTs in certain applications.

Market Opportunities:

The LDT market offers substantial growth opportunities driven by continued innovation in diagnostics and the expanding scope of precision medicine. The increasing integration of artificial intelligence and bioinformatics into laboratory testing presents new possibilities for more accurate and efficient test development. Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing improved healthcare infrastructure and diagnostic capabilities, opening up new avenues for LDT adoption. Moreover, as demand grows for early disease detection and targeted therapies, LDTs are well-positioned to play a central role in niche diagnostic areas such as rare diseases and pharmacogenomics. Partnerships between academic research centers and commercial diagnostic companies can also accelerate LDT development and market reach.

Key Questions Answered in the Report:

• What are the primary factors driving the global Laboratory Developed Test market's growth?
• Which regions and application areas are experiencing the highest demand for LDTs?
• How are technological innovations in molecular diagnostics shaping the LDT landscape?
• Who are the key players in the Laboratory Developed Test market, and what strategies are they adopting to remain competitive?
• What are the regulatory developments and future projections for the global LDT market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Laboratory Developed Test market, such as Thermo Fisher Scientific Inc., QIAGEN, Roche Diagnostics, and Quest Diagnostics, are focusing on expanding their test portfolios, particularly in oncology, infectious diseases, and genetic testing. These companies are leveraging strategic collaborations with academic institutions, biotech firms, and healthcare providers to enhance innovation and accelerate time-to-market for novel assays. Investment in automation, AI-based data analysis tools, and next-generation sequencing technologies is enabling improved test accuracy and throughput. Furthermore, companies are engaging with regulatory bodies to ensure compliance and support smoother transitions under evolving LDT regulations.

Companies Covered in This Report:

• Thermo Fisher Scientific Inc.
• Kaneka Eurogentec S.A.
• QIAGEN
• Vastian
• Roche Diagnostics
• Adaptive Biotechnologies
• Guardant Health, Inc.
• Smiths Medical
• Quest Diagnostics
• Beckman Coulter
• OPKO Health, Inc.

Laboratory Developed Test Market Segmentation:

By Test Type:

• Clinical Biochemistry
• Haematology
• Immunology
• Microbiology
• Molecular Diagnostics
• Others

By Application:

• Oncology
• Genetics
• Infectious Diseases
• Autoimmune Disorders
• Others

By End User:

• Hospital Laboratories
• Specialty Diagnostics Centers
• Clinical Research Organizations
• Research Institutes
• Others

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Laboratory Developed Test Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Regulatory Landscape
• 3.3. Reimbursement Scenario
• 3.4. PESTLE Analysis
• 3.5. Promotional Strategies, By Key Players

4. Global Laboratory Developed Test Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
• 4.3. Global Laboratory Developed Test Outlook: Test Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2024
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 4.3.3.1. Clinical Biochemistry
    • 4.3.3.2. Hematology
    • 4.3.3.3. Immunology
    • 4.3.3.4. Microbiology
    • 4.3.3.5. Molecular Diagnostics
    • 4.3.3.6. Others
  • 4.3.4. Market Attractiveness Analysis: Test Type
• 4.4. Global Laboratory Developed Test Outlook: Application
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Bn), By Application, 2019-2024
  • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 4.4.3.1. Oncology
    • 4.4.3.2. Genetics
    • 4.4.3.3. Infectious Diseases
    • 4.4.3.4. Autoimmune Disorders
    • 4.4.3.5. Other Conditions
  • 4.4.4. Market Attractiveness Analysis: Application
• 4.5. Global Laboratory Developed Test Outlook: End User
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn), By End User, 2019-2024
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 4.5.3.1. Hospital Laboratories
    • 4.5.3.2. Specialty Diagnostics Centers
    • 4.5.3.3. Clinical Research Organizations
    • 4.5.3.4. Research Institutes
    • 4.5.3.5. Others
  • 4.5.4. Market Attractiveness Analysis: End User

5. Global Laboratory Developed Test Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Laboratory Developed Test Outlook

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Test Type
  • 6.2.3. By Application
  • 6.2.4. By End User
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
  • 6.4.1. Clinical Biochemistry
  • 6.4.2. Hematology
  • 6.4.3. Immunology
  • 6.4.4. Microbiology
  • 6.4.5. Molecular Diagnostics
  • 6.4.6. Others
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 6.5.1. Oncology
  • 6.5.2. Genetics
  • 6.5.3. Infectious Diseases
  • 6.5.4. Autoimmune Disorders
  • 6.5.5. Other Conditions
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
  • 6.6.1. Hospital Laboratories
  • 6.6.2. Specialty Diagnostics Centers
  • 6.6.3. Clinical Research Organizations
  • 6.6.4. Research Institutes
  • 6.6.5. Others
• 6.7. Market Attractiveness Analysis

7. Europe Laboratory Developed Test Outlook

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Test Type
  • 7.2.3. By Application
  • 7.2.4. By End User
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
  • 7.4.1. Clinical Biochemistry
  • 7.4.2. Hematology
  • 7.4.3. Immunology
  • 7.4.4. Microbiology
  • 7.4.5. Molecular Diagnostics
  • 7.4.6. Others
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 7.5.1. Oncology
  • 7.5.2. Genetics
  • 7.5.3. Infectious Diseases
  • 7.5.4. Autoimmune Disorders
  • 7.5.5. Other Conditions
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
  • 7.6.1. Hospital Laboratories
  • 7.6.2. Specialty Diagnostics Centers
  • 7.6.3. Clinical Research Organizations
  • 7.6.4. Research Institutes
  • 7.6.5. Others
• 7.7. Market Attractiveness Analysis

8. East Asia Laboratory Developed Test Outlook

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Test Type
  • 8.2.3. By Application
  • 8.2.4. By End User
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
  • 8.4.1. Clinical Biochemistry
  • 8.4.2. Hematology
  • 8.4.3. Immunology
  • 8.4.4. Microbiology
  • 8.4.5. Molecular Diagnostics
  • 8.4.6. Others
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 8.5.1. Oncology
  • 8.5.2. Genetics
  • 8.5.3. Infectious Diseases
  • 8.5.4. Autoimmune Disorders
  • 8.5.5. Other Conditions
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
  • 8.6.1. Hospital Laboratories
  • 8.6.2. Specialty Diagnostics Centers
  • 8.6.3. Clinical Research Organizations
  • 8.6.4. Research Institutes
  • 8.6.5. Others
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Laboratory Developed Test Outlook

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Test Type
  • 9.2.3. By Application
  • 9.2.4. By End User
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
  • 9.4.1. Clinical Biochemistry
  • 9.4.2. Hematology
  • 9.4.3. Immunology
  • 9.4.4. Microbiology
  • 9.4.5. Molecular Diagnostics
  • 9.4.6. Others
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 9.5.1. Oncology
  • 9.5.2. Genetics
  • 9.5.3. Infectious Diseases
  • 9.5.4. Autoimmune Disorders
  • 9.5.5. Other Conditions
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
  • 9.6.1. Hospital Laboratories
  • 9.6.2. Specialty Diagnostics Centers
  • 9.6.3. Clinical Research Organizations
  • 9.6.4. Research Institutes
  • 9.6.5. Others
• 9.7. Market Attractiveness Analysis

10. Latin America Laboratory Developed Test Outlook

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Test Type
  • 10.2.3. By Application
  • 10.2.4. By End User
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
  • 10.4.1. Clinical Biochemistry
  • 10.4.2. Hematology
  • 10.4.3. Immunology
  • 10.4.4. Microbiology
  • 10.4.5. Molecular Diagnostics
  • 10.4.6. Others
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 10.5.1. Oncology
  • 10.5.2. Genetics
  • 10.5.3. Infectious Diseases
  • 10.5.4. Autoimmune Disorders
  • 10.5.5. Other Conditions
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
  • 10.6.1. Hospital Laboratories
  • 10.6.2. Specialty Diagnostics Centers
  • 10.6.3. Clinical Research Organizations
  • 10.6.4. Research Institutes
  • 10.6.5. Others
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Laboratory Developed Test Outlook

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Test Type
  • 11.2.3. By Application
  • 11.2.4. By End User
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
  • 11.4.1. Clinical Biochemistry
  • 11.4.2. Hematology
  • 11.4.3. Immunology
  • 11.4.4. Microbiology
  • 11.4.5. Molecular Diagnostics
  • 11.4.6. Others
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 11.5.1. Oncology
  • 11.5.2. Genetics
  • 11.5.3. Infectious Diseases
  • 11.5.4. Autoimmune Disorders
  • 11.5.5. Other Conditions
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
  • 11.6.1. Hospital Laboratories
  • 11.6.2. Specialty Diagnostics Centers
  • 11.6.3. Clinical Research Organizations
  • 11.6.4. Research Institutes
  • 11.6.5. Others
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. QIAGEN
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Test Types
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Thermo Fisher Scientific Inc.
    • 12.3.2.1. Overview
    • 12.3.2.2. Segments and Test Types
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Kaneka Eurogentec S.A.
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Test Types
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. Vastian
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Test Types
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Roche Diagnostics
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Test Types
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. Adaptive Biotechnologies.
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Test Types
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. Guardant Health, Inc.
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Test Types
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. Smiths Medical
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Test Types
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. Quest Diagnostics
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Test Types
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. Beckman Coulter
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Test Types
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. OPKO Health, Inc.
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Test Types
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. Siemens Medical Solutions USA, Inc.
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Test Types
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Quanterix
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Test Types
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy
  • 12.3.14. Proteomics International
    • 12.3.14.1. Overview
    • 12.3.14.2. Segments and Test Types
    • 12.3.14.3. Key Financials
    • 12.3.14.4. Market Developments
    • 12.3.14.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료